Covered recipient · General Payments record
SHILPA GUPTA
Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology
General Payments · PY2018–2024
$3,264.01
- Reported across 72 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $361.18 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ascendis Pharma Inc | $150.75 | 6 |
| TOLMAR, INC. | $89.47 | 4 |
| Novo Nordisk AS | $42.90 | 2 |
| SANOFI PASTEUR INC. | $24.80 | 1 |
| ABBVIE INC. | $20.63 | 1 |
| Insulet Corporation | $16.71 | 1 |
| DEXCOM, INC. | $15.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.63 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853815 | CMS |
| Ascendis Pharma Inc | $19.40 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133843710 | CMS |
| Ascendis Pharma Inc | $23.05 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133844540 | CMS |
| Ascendis Pharma Inc | $29.89 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133845093 | CMS |
| Ascendis Pharma Inc | $30.02 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133845868 | CMS |
| Ascendis Pharma Inc | $21.72 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133847230 | CMS |
| Ascendis Pharma Inc | $26.67 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133847683 | CMS |
| Dexcom, Inc. | $15.92 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153336395 | CMS |
| Insulet Corporation | $16.71 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116792708 | CMS |
| Novo Nordisk Inc | $21.45 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097825304 | CMS |
| Novo Nordisk Inc | $21.45 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097313860 | CMS |
| SANOFI PASTEUR INC. | $24.80 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128754157 | CMS |
| Tolmar, Inc. | $28.29 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138712154 | CMS |
| Tolmar, Inc. | $26.01 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138712156 | CMS |
| Tolmar, Inc. | $18.92 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138712158 | CMS |
| Tolmar, Inc. | $16.25 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138711038 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.